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Background: Metabolic syndrome (MetS) is associated with increased risk of cardiovascular disease (CVD). One important
feature underlying the pathophysiology of many types of CVD is microvascular dysfunction. Although components of
MetS are themselves CVD risk factors, the risk is increased when the syndrome is considered as one entity. We aimed to
characterize microvascular function and some of its influencing factors in the course of MetS development.
Methods: Development of MetS in C57BL/6 mice on a high-fat diet (HFD, 51% of energy from fat) was studied. The initial
phase of MetS (I-MetS) was defined as the first 2 weeks of HFD feeding, with the fully developed phase occurring after
8 weeks of HFD. We characterized these phases by assessing changes in adiposity, blood pressure, and microvascular
function. All data are presented as mean ± standard error (SEM). Differences between cumulative dose–response curves of
myograph experiments were calculated using non-linear regression analysis. In other experiments, comparisons between
two groups were made with Student’s t-test. Comparisons between more than two groups were made using one-way
ANOVA with Tukey post-hoc test. A probability value <0.05 was considered statistically significant.
Results: I-MetS mice presented with weight gain, blood pressure elevation, and microvascular dysfunction characterized
by augmented vasoconstriction. This finding, contrary to those in mice with fully developed MetS, was not associated
with endothelial dysfunction, insulin resistance, or systemic inflammation. In the initial phase, perivascular adipose tissue
showed no sign of inflammation and had no influence on the pattern of vasoconstriction. These findings suggest that
the onset of hypertension in MetS is strongly influenced by vascular smooth muscle cell dysfunction and independent of
important factors known to influence microvascular function and consequently blood pressure levels.
Conclusion: We identified in I-MetS the occurrence of isolated augmented vasoconstriction along with blood pressure
elevation, but not the presence of classical MetS components known to influence microvascular function. These findings
increase our understanding of the pathophysiology of CVD risk associated with MetS.
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Cardiovascular disease (CVD) is the leading cause of
death worldwide. Although highly influenced by non-
modifiable risk factors such as age, family history, and
gender, CVD is largely caused by risk factors that can be
treated or at least controlled [1]. Most of the modifiable
risk factors are disorders typically associated with obesity* Correspondence: Marcus.baumann@lrz.tum.de
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stated.that commonly cluster together, such as abdominal
obesity, insulin resistance, dyslipidemia, and hyperten-
sion. These disorders are components of the so-called
metabolic syndrome (MetS) [2]. Different clinical criteria
have been proposed as being diagnostic of MetS. The
National Cholesterol Education Program Adult Treat-
ment Panel III definition is one of those most widely
used [3], and defines MetS as the occurrence of three or
more of the following five criteria: waist circumference
over 102 cm (men) or 88 cm (women), blood pressure ≥
130/85 mmHg, fasting triglyceride level ≥ 150 mg/dl,
fasting high-density lipoprotein cholesterol level lesstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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glucose level ≥ 100 mg/dl. The association between MetS
and a high risk of developing CVD is extensively re-
ported in the literature [4-6].
Regarding the underlying processes of CVD develop-
ment, key components appear to be structural and func-
tional alterations of the microvasculature, laying the
foundations for target organ damage [7]. The microvascu-
lature consists of the smallest arteries, the arterioles, capil-
laries, and venules [8], therefore including the so-called
resistance arteries, which consist mainly of arteries
<400 μm and arterioles <100 μm in lumen diameter [9].
Dysfunction of the microvasculature has been associated
with features of MetS and has been reported in different
ways [10-12]. MetS components, such as insulin resist-
ance, dyslipidemia, arterial hypertension, and abdominal
obesity, can independently influence microvascular func-
tion [13-16]. In obesity, pathological adipose tissue is asso-
ciated with microvascular dysfunction [16,17], and, more
specifically, perivascular adipose tissue (PVAT) is now ac-
cepted to be an important modulator of vascular function
[16,18,19]. Vascular anticontractile properties of PVAT
were described to be mediated through the hormone adi-
ponectin [16]. In Zucker lean rats, adiponectin provoked
vasodilation of mesenteric arteries, dependent on nitric
oxide (NO). In their diabetic littermates, the Zucker Dia-
betic Fatty rats, the vasodilation caused by adiponectin
was diminished and associated with endothelial dysfunc-
tion [20]. Controversy surrounds the theory that restoring
adiponectin levels is associated with improvement in
endothelial function [21,22]. More recently, contractile
properties of adiponectin were also identified, related to
alterations in the PVAT proteome in obesity [23]. Thus,
the precise characteristics of microvascular dysfunction
observed in MetS remain unclear owing to the simultan-
eous occurrence of different disorders and their complex
interaction.
In rodents, hormonal, metabolic, and cardiovascular dis-
orders induced by hypercaloric diets are widely reported.
Oliveira et al. reported that hyperglycemia, systolic blood
pressure disorders, and cardiac remodeling were induced
by a hypercaloric diet for 20 weeks in Wistar-Kyoto rats
[24]. Sarkozy et al. reported features of MetS in Zucker
Diabetic Fatty rats associated with altered cardiac expres-
sion of genes related to metabolism, signal transduction,
stress response, and receptors [25]. In this study, we used
the C57BL/6 mouse, which is a model widely used to
study diet-induced obesity as it develops features observed
in human MetS [26]. We assessed microvascular function
through the mesenteric arterial arcade [27], which, in ro-
dents, contributes substantially to regulation of peripheral
resistance [28] and blood pressure [29].
We aimed to characterize features of microvascular
function during MetS development in a mouse model,particularly during the initial phase when confounding
factors known to influence microvascular function are
not completely established. In addition, we investigated
the influence of endothelium and PVAT, two important




Male wild-type C57BL/6 J (WT) mice were housed in
temperature-controlled cages (20°C to 22°C) and main-
tained on a 12/12-hour light/dark cycle. At the age of
12 weeks mice were randomly assigned to either a con-
trol diet (9% of calories from fat, 33% from protein, and
58% from carbohydrates) or to a high-fat diet (HFD, 51%
from fat, 23% from protein, and 26% from carbohy-
drates). Both diets were purchased from Ssniff (Soest,
Germany). We defined the group who received HFD for
8 weeks as the metabolic syndrome group (MetS) and
HFD for 2 weeks as the initial metabolic syndrome
group (I-MetS). WT mice were obtained from Charles
River Laboratories (Sulzfeld, Germany). During isoflur-
ane anesthesia mice were fixed on a heat-controlled
plate and an intra-arterial pressure transducer was
inserted in the left carotid artery under sterile condi-
tions. Intra-arterial blood pressure was measured con-
tinuously for 15 minutes (Blood Pressure Monitor BP1,
World Precision Instruments, Sarasota, FL, USA).
Thereafter, animals were sacrificed and the entire intes-
tine, including vascular arcades, was immediately excised
and stored in cold 3-(N-morpholino)propanesulfonic
acid (MOPS) buffer for wire myograph studies. Changes
in whole body weight and epididymal fat pad weight
were assessed as parameters of visceral fat status.
Serum was collected in serum separator tubes (Sarstedt,
Nümbrecht, Germany) and stored at −80°C for subse-
quent experiments. All animals received humane care
and all animal protocols were fully compliant with the
principles of the Guide for the Care and Use of Labora-
tory Animals from the National Institutes of Health and
German Law on the Protection of Animals was followed.
The protocol was approved by the government of Bayern’s
Animal Care Committee, Regierung von Oberbayern,
Munich, Germany (Protocol number: AZ 55.2-1-54-2531-
19-09). The mice were observed daily for any signs of dis-
tress and weighed weekly to monitor health. Blood pressure
measurement in the carotid artery was performed under
isoflurane anesthesia, and termination was performed with
cervical dislocation. All efforts were made to minimize
suffering.
Magnetic resonance imaging
Whole body magnetic resonance imaging (MRI) was
performed on mice anesthetized with intraperitoneal
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mm microscopy surface coil inside the clinical 1.5 T
MRI System (Achieva 1.5 T, Philips Medical Systems,
Best, The Netherlands). An axial, multi-slice, turbo spin
echo sequence [resolution 0.25 × 0.25 × 0.35 mm3, 140
slices, echo time (TE) = 100 ms, repetition time (TR) =
1000 ms was applied to suppress signal from tissue other
than fat. The whole body images were reconstructed
using an OsiriX DICOM viewer.
Biochemical measurements
Serum fasting total cholesterol, triglycerides, and glucose
levels were measured by enzymatic methods (Roche
Diagnostics). Fasting insulin was measured by enzyme-
linked immunosorbent assay (ELISA) kit (Shibayagi,
Shibukawa, Japan). The insulin resistance index [homeo-
stasis model assessment (HOMA-IR)] was calculated using
fasting insulin and glucose values: [insulin (picomoles per
liter) × glucose (millimoles per liter)]/22.5 [30,31]. Serum
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)
were measured with murine ELISA kits (Peprotech,
Hamburg, Germany). Dissected mesenteric PVAT was
snap-frozen and protein extracts were used for Rho-
associated kinase activity measurement by an enzyme
immunoassay (Cell Biolabs, San Diego, CA, USA). Mea-
surements were performed according to the manufac-
turer’s protocol using 10 μg of protein lysate. Values are
reported as percentage of activity related to controls.
Histology
Epididymal fat pads and mesenteric vascular beds with
PVAT were fixed in paraformaldehyde, embedded in
paraffin, and subsequently stained with hematoxylin-
eosin. For each mouse, the area of 50 randomly chosen
adipocytes was measured in five representative sections
using Image J software (National Institutes of Health,
USA) at 10× magnification. Mean values given in pixels
were compared. Analysis of infiltrating leukocytes in
mesenteric PVAT was performed by immunohistochemi-
cal staining for CD45 (Becton & Dickenson, Franklin
Lakes, NJ, USA). The total number of CD45-positive
cells was counted in ten randomly chosen arteries per
whole mesenteric vascular bed per mouse and the aver-
age calculated.
Two-photon microscopy
Small mesenteric arteries and correspondent PVAT were
visualized using a Leica SP5 II MP two-photon laser
scanning microscope coupled with a water dipping 20×
NA 1.00 objective and a pre-chirped Ti:Sa laser (Spectra
Physics, Springfield, OH, USA) tuned to 840 nm [32].
Four hybrid detectors (HyD) were spectrally tuned for
optimal detection efficiency and low bleed through of
signal: second harmonic generation of collagen (HyD1:400–425 nm), autofluorescence of adipocytes and GR1/
eFluor450 (HyD2: 445–500 nm), autofluorescence of
adipocytes/elastin, and CD115/Alexa488 (HyD3: 515–
555 nm) CD45/nanocrystal-605 nm (HyD4: 590–
625 nm). Additional image processing was performed
using Leica LAF AF 3.0 and ImagePro. Quantification of
inflammatory cells was performed by detecting the num-
ber of cells positive for CD45/CD115 (monocyte and
macrophage marker) and for CD45/Gr-1 (marker for
neutrophil in peripheral organs) in each arterial segment
recorded in 3D datasets (n = 3 arterial segments per
mouse, n = 4 mice per group). All antibodies were from
eBioscience (San Diego, CA, USA). We counted the num-
ber of inflammatory cells using 3D datasets from the PVAT
of the small mesenteric arteries (up to a distance of three
times the average adipocyte diameter from the small ar-
tery). The adipocyte volume was determined by measuring
maximal diameter in the corresponding arterial segment,
assuming a spherical cell shape. The total number of posi-
tive cells is presented as inflammatory cells per adipocyte.
RNA isolation and real-time polymerase chain reaction
Dissected mesenteric PVAT was snap-frozen in liquid
nitrogen and stored at −80°C. Then, 80 mg of tissue was
used for RNA isolation using RNeasy Lipid Tissue mini
kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. Quality of RNA was assessed using
Bioanalyzer (BioRad, Hercules, CA, USA). Complemen-
tary DNA was synthesized using iScript cDNA Synthesis
Kit (BioRad), according to the manufacturer’s protocol.
Quantitative reverse transcriptase polymerase chain re-
action (PCR) was performed using SYBR Green I (MyiQ
ICycler, Bio-Rad). Gene expression of TNF-α, IL-6,
monocyte chemotactic protein-1 (MCP-1), Toll-like re-
ceptor 4 (TLR4), RhoA, Rho-kinase 1 (ROCK1), and
Rho-kinase 2 (ROCK2) were investigated. cDNA primers
(sense and anti-sense) were as follows: glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (TCGGTGTGAAC
GGATTTGGC and TTTGGCTCCACCCTTCAAGTG),
TNF-α (CCAAAGGGATGAGAAGTTCC and GGCA-
GAGAGGAGGTTGACTTT), IL-6 (CTGGGAAATCG
TGGAAATGAG and ACTCTGGCTTTGTCTTTCT
TG), MCP-1 (GCTGTAGTTTTTGTCACCAAG and
GATTTACGGGTCAACTTCACA), TLR4 (ATTCCCT-
CAGCACTCTTGATT and AGTTGCCGTTTCTTGTT
CTTC), RhoA (CTCTCTTATCCAGACACCGAT and
CAAAAACCTCTCTCACTCCATC), ROCK 1 (AAGG
CGGTGATGGCTATTATG and TCCTCTACACCATT
TCTGCCC), and ROCK 2 (ATGTGATTGGTGGTCTG-
TAGGT and AGCTGCCGTCTCTCTTATGTTA). Qu-
antification was made using the ddCt algorithm, including
normalization of each sample to GAPDH [33]. The results
are expressed as the multiple of the control value from
three independent experiments.
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Total adiponectin and adiponectin multimers were deter-
mined by Western blotting in serum. Sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) was
performed. In brief, serum proteins were separated by 10%
SDS-PAGE under non-reducing and non-heating condi-
tions, and transferred to nitrocellulose membranes. Mem-
branes were blocked with Tris-buffered saline-Tween 20
containing 5% skim milk and incubated with a goat anti-
human adiponectin polyclonal antibody (1:500). After
washing, membranes were incubated with horseradish
peroxidase conjugated-donkey anti-goat antibody (1:4000).
Bands were visualized by using lumi-light Western blot-
ting substrate, and the image was acquired with a Kodak
IS440CF Imaging Station. Densitometry analysis was per-
formed with Adobe Photoshop software. Relative distribu-
tions of adiponectin multimers were calculated by dividing
band density by total density.
Wire myograph and microvascular studies
First- to second-order branches from the superior mesen-
teric artery (270–330 μm) were cleaned of PVAT, cut into
2-mm-long rings, and mounted in a 4-channel wire myo-
graph (Model 620 M, Danish Myo Technology, Aarhus,
Denmark). Each vessel segment was mounted on two
tungsten wires (40 μm diameter) in the organ chamber
filled with MOPS buffer. MOPS buffer consisted of (in
mM): NaCl 145, KCl 4.7, CaCl2 3.0, MgSO4 1.17,
NaH2PO4 1.2, pyruvate 2.0, EDTA 0.02, MOPS 3.0, and
glucose 5.0. Vessels were pre-stretched to a tension repre-
senting a blood pressure of 13.3 kilopascal and equili-
brated at this tension for 30 minutes at 37°C [34].
Subsequently, the organ bath solution was changed for a
fresh pre-heated MOPS buffer and vascular functions were
analyzed. During the experiments, the diameter of the ves-
sels was kept constant, so the vessels could be examined
under isometric conditions. For testing viability, vessels
were subjected to norepinephrine-induced constriction
followed by acetylcholine. Vessels with endothelium-
dependent relaxation in the presence of acetylcholine that
was greater than 70% of the maximal norepinephrine
vasoconstriction were considered to have an intact endo-
thelium. After washing out with MOPS buffer and resting
for 20 min, norepinephrine (10−9 to 10−5 M) and acetyl-
choline (10−10 to 10−5 M) dose–response curves were con-
structed. Relaxation of preconstricted (high potassium
chloride, 125 mM) vessels in response to an external
NO donor (sodium nitroprusside, 10−10 to 10−5 M) was
measured. Response was expressed as a percentage of
potassium-induced constriction.
In the set of experiments designed to study the influ-
ence of PVAT on vascular response, one segment of a
small mesenteric artery was cleaned of PVAT while the
adjacent segment was left uncleaned. Arteries were firstconstricted with norepinephrine (10−5 M) to obtain the
baseline response. After washing and resting for 20 min,
norepinephrine dose–response curves were constructed,
where the response was expressed as a percentage of the
baseline norepinephrine-induced contraction.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SEM). In cumulative dose–response curves of
myograph experiments, the logEC50 value for tissue
from each mouse (two to four arteries per mouse) was
calculated. Differences between logEC50 values were cal-
culated using non-linear regression analysis. In other ex-
periments, comparisons between two groups were made
with Student’s t-test. For comparisons between more
than two groups, one-way ANOVA with Tukey post-hoc
test was used. A probability value of <0.05 was consid-
ered statistically significant (GraphPad Prism ® 5.0).
Results
A mouse model to investigate the initial phase of
metabolic syndrome
A high-fat diet was used to induce features of MetS in
WT mice. As expected, WT mice fed a HFD for 8 weeks
(MetS group) gained a significant amount of weight, and
showed a marked increase in visceral fat tissue (mesen-
teric PVAT and epididymal fat pads) and hypertrophy of
adipocytes. Mean arterial blood pressure was significantly
elevated (control: 70.5 ± 2.1 mmHg vs. MetS: 82.7 ±
1.6 mmHg, P < 0.01) (Figure 1A). MetS group mice also
presented with insulin resistance and systemic inflamma-
tion, as measured by increases in HOMA-IR and serum
TNF-α level, respectively (Figure 1C).
Compared with controls, mice fed a HFD for 2 weeks
(I-MetS group) also had significantly heavier epididymal
fat pads and increased mesenteric PVAT, accompanied
by adipocyte hypertrophy (Figure 1B). However, disor-
ders associated with MetS, such as insulin resistance and
systemic inflammation, were not present (Figure 1C).
Mean arterial blood pressure was significantly elevated
in I-MetS group mice, as was observed in the MetS
group (control: 72 ± 1.3 mmHg vs. I-MetS: 85 ±
1.0 mmHg, P < 0.001) (Figure 1B).
The initial phase of MetS presents with augmented
vasoconstriction, independent of endothelium and PVAT
In MetS mice, small mesenteric arteries had an augmented
response to the vasoconstrictor norepinephrine, demon-
strated by measurement of sensitivity (control: logEC50
−6.170 vs. MetS: logEC50 −6.664, P < 0.001). In MetS
mice, relaxation in response to acetylcholine was signifi-
cantly lower compared with control, and that to sodium
nitroprusside was significantly augmented (Figure 2A). I-
MetS group mice also had increased sensitivity to
Figure 1 Features of metabolic syndrome in WT mice. A, After a HFD for 8 weeks (Metabolic Syndrome=MetS) and B, 2 weeks (Initial Metabolic
Syndrome = I-MetS), there was increase in visceral fat tissue seen in mesenteric PVAT, epididymal fat pads, adipocyte hypertrophy and hyperintense areas
displaying fat depots in magnetic resonance imaging. Elevation of blood pressure was seen in MetS and I-MetS groups. C, Comparative table of weight
and metabolic parameters (n = 10–15 mice/group). Data are presented as mean ± SEM, n = 10-20 mice/group, **P <0.01, ***P< 0.001, na = not applicable.
Figure 2 Microvascular function in MetS and I-MetS mice. A, Norepinephrine-induced vasoconstriction was significantly increased, acetylcholine-
induced relaxation was reduced and responses to sodium nitroprusside were increased in MetS mice. B, Similarly to MetS, the I-MetS group also presented
increased vasoconstriction but without differences in relaxation responses. Data are presented as mean ± SEM, n = 10 mice/group, *P< 0.05, ***P< 0.001.
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logEC50 −6.556, P < 0.001), but relaxation responses to
acetylcholine and sodium nitroprusside were the same as
seen in control mice (Figure 2B). Mechanical removal of
the endothelium (Figure 3A) did not affect the pattern of
vasoconstriction responses in arteries from MetS and I-
MetS mice, suggesting that these vascular findings are at
least partially independent of endothelium integrity
(Figure 3B).
Next, we investigated mesenteric PVAT. Infiltration by
inflammatory cells was first investigated by immunohis-
tochemistry. The number of cells positive for the pan-
leukocyte marker CD45 was increased only in MetS
mice and not in the I-MetS group (Figure 4A). Two-
photon microscopic imaging of small mesenteric arteries
surrounded by PVAT showed that the number of cells
positive for CD45/CD115 (monocytes and macrophages)
and CD45/Gr-1 (neutrophils) tended to increase (P =
0.06) in the PVAT from just MetS mice (Figure 4B).
Gene expression of inflammatory markers, such as
MCP-1 and TLR4, were significantly increased in the
PVAT from just MetS mice (Figure 4C).
To investigate the influence of PVAT in vasoconstric-
tion responses we examined arteries with and without
this tissue. In control mice, PVAT has an anticontractile
effect (Figure 5A). The data obtained strongly suggest
that, in I-MetS mice, PVAT keeps its anticontractile
properties (Figure 5B), whereas the MetS group has lostFigure 3 Effect of endothelium removal on vasoconstriction response
test showing no relaxation response to acetylcholine. B, Endothelium-denude
increased vasoconstriction responses compared to controls. Data are presentethis characteristic (Figure 5C). Among the reported
PVAT-derived effectors that can influence vascular con-
tractility are adiponectin levels and activation of the
RhoA/Rho-kinase pathway. Adiponectin is present in
the circulation as three distinct oligomeric complexes
[35] and it has been described as having a key role in
modulating vascular function [16]. However, in I-MetS
mice, levels of adiponectin, and in particular of high-
molecular weight (HMW) adiponectin, were unchanged
compared with controls. In contrast, MetS mice had sig-
nificantly reduced HMW adiponectin (Figure 5D). In the
PVAT from MetS mice (Figure 6A), gene expression of
the small GTPase RhoA and of two of its downstream
effectors, ROCK1 and ROCK2, was increased. In MetS
mice Rho-kinase activity was increased, but this was not
observed in the PVAT from I-MetS mice (Figure 6B). To
summarize, in contrast with MetS mice, I-MetS mice ex-
hibited augmented vasoconstriction that was independ-
ent of PVAT and some of its described vasoactive
effectors.
Discussion
This study was designed to investigate microvascular
function during the development of MetS induced by
HFD. We showed that microvascular dysfunction in the
form of augmented vasoconstriction was already present
in the initial phase of MetS, as was blood pressure eleva-
tion. These early vascular alterations developed in thes. A, Mechanical removal of endothelium with a human hair and viability
d arteries from both MetS and I-MetS groups still presented significantly
d as mean ± SEM, n = 4–5 mice/group, **P <0.01, ***P < 0.001.
Figure 4 Inflammatory cell infiltration in mesenteric perivascular adipose tissue (PVAT). A, Representative images of CD45
immunohistochemical staining of a small mesenteric artery and surrounding PVAT. The number of CD45-positive cells was not different between I-MetS
mice and controls, but it was increased in MetS mice (data are presented as mean ± SEM, n = 6 mice/group, *P< 0.05, scale bars = 50 μm). B, Representative
images of two-photon microscopy of a small mesenteric artery on the left, with the surrounding PVAT stained for CD45/CD115 and CD45/Gr-1. I-MetS mice
did not present with increased number of positive cells. In MetS mice there was a trend toward more positive cells (P= 0.06, scale bars = 100 μm). The
column graph represents the number of positive cells per arterial segment examined (data are presented as mean ± SEM, 3 segments/mouse, n = 4
mice/group). C, In contrast with MetS mice, I-MetS mice did not present increased expression of inflammatory genes in mesenteric PVAT. Results represent
three independent experiments, n = 3–4 mice/group, data are presented as mean ± SEM, *P< 0.05, **P< 0.01.
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vascular function, such as insulin resistance, systemic in-
flammation, and endothelial and PVAT dysfunction,
which were only observed in a later phase of MetS.
Microvascular dysfunction was present already in the
initial phase of metabolic syndrome
Prolonged HFD in C57BL/6 mice is an established model
of diet-induced MetS [26]. In our study I-MetS mice pre-
sented with mild weight gain, a prominent visceral fat
increase, hypercholesterolemia, and blood pressure eleva-
tion; however, systemic inflammation and insulin resist-
ance were not observed. After 8 weeks of HFD, mice
presented with features similar to those found in human
MetS, such as weight gain with a marked increase in vis-
ceral fat, hypercholesterolemia, and blood pressure eleva-
tion. In addition to these classical components, MetS mice
presented with insulin resistance and systemic inflamma-
tion indicated by elevated TNF-α and reduced adiponectin
levels. These factors are part of the additional metabolic
criteria suggested for research by the International Dia-
betes Federation, aiming at further modification of the
MetS definition [36].Concerning the microvasculature, MetS mice pre-
sented with augmented vasoconstriction responses to
norepinephrine, while the relaxation responses to acetyl-
choline and sodium nitroprusside were reduced and aug-
mented, respectively, suggesting endothelial dysfunction.
Similarly, augmented vasoconstriction in the presence of
norepinephrine was present in I-MetS mice. However,
contrary to MetS mice, relaxation induced by acetylcho-
line and sodium nitroprusside was preserved in I-MetS
mice, suggesting the integrity of endothelial function.
Obesity is reported to be associated with impaired NO
bioavailability with a compensatory increase in the activ-
ity of soluble guanylyl cyclase [37], the major cellular re-
ceptor for NO. The augmented relaxation responses to
sodium nitroprusside, an external source of NO, suggest
impaired NO bioavailability and, together with decreased
relaxation responses to acetylcholine, strongly suggest
diminished endothelial function. Therefore, augmented
vasoconstriction in the absence of endothelial dysfunc-
tion as observed in I-MetS mice strengthens the evi-
dence of a role for vascular smooth muscle cells. It
is known that endothelial function can be influenced
by the presence of insulin resistance [14], systemic
Figure 5 Role of PVAT in vascular responses and adiponectin measurement. A, Arteries examined in the myograph without and with PVAT,
control mice. B, I-MetS mice showed PVAT with anticontractile properties similar to control mice. C, MetS mice did not present with this effect anymore
(Data presented as mean ± SEM, n = 4 mice/group, ***P < 0.001). D, Lower levels of high-molecular weight (HMW) adiponectin in relation to total
adiponectin in serum were seen only in MetS mice (Data presented as mean ± SEM, n = 5 mice/group, *P <0.05, ns = not significant).
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[16,39]; therefore, association of these factors in MetS
mice was expected. In contrast to these findings in MetS
mice, the augmented vasoconstriction in I-MetS mice
was independent of endothelial dysfunction, insulin re-
sistance, and systemic inflammation.
Human MetS has been associated with an increased risk
of CVD such as myocardial infarction, stroke [40], and cor-
onary microvascular dysfunction linked to a microvascular
form of angina pectoris [11]. Microvascular dysfunction is
reported to be associated with poor cardiovascular outcomes
[41,42], including left ventricular remodeling [43]. Thus,
identification of specific MetS components that are associ-
ated with microvascular dysfunction might help illuminate
the pathophysiology of CVD in MetS. The community-
based Bogalusa Heart Study evaluated normotensive, prehy-
pertensive, and hypertensive adults. The study showed thatthe early natural history of hypertension was characterized
by excess adiposity and blood pressure beginning in child-
hood and unfavourable changes in risk variables of MetS
occuring through young adulthood. Importantly, our study
showed that, as in MetS mice, I-MetS mice presented with
blood pressure elevation plus augmented vasoconstriction,
suggesting that there is a close relationship between these
features because the microcirculation actively regulates
blood pressure control [8]. Therefore, augmented vasocon-
striction could underlie the onset of hypertension in MetS.
Dysfunction of adipose tissue was absent in the initial
phase of metabolic syndrome
The vasoactive properties of PVAT are now recognized
as being protective in healthy conditions [16]. However,
in the setting of obesity, for example, inflammation in
adipose tissue, such as that caused by macrophage
Figure 6 Activation of RhoA/Rho-kinase pathway in mesenteric PVAT. A, Mesenteric PVAT from MetS mice showed increased gene
expression of RhoA and Rho-kinases. Rho-kinase activity was also significantly increased, which was not seen in I-MetS mice (B). Data represent
the mean ± SEM from 2–4 independent experiments, n = 3–4 mice/group, *P < 0.05, **P < 0.01.
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vascular effect [23,45]. In our study, mice with I-MetS
did not show signs of dysfunctional PVAT, presenting
with neither infiltration by inflammatory cells nor in-
creased expression of inflammatory genes. Loss of the
anticontractile effect was only seen in MetS mice and
not in the I-MetS group. Activation of the renin-
angiotensin–aldosterone system [46,47] is involved in
diet-induced obesity, since hypertrophied adipocytes can
serve as a source of angiotensin II [48]. Although our
experiments do not rule out the role of angiotensin II in
early stages of disease development, the PVAT had a
protective role in vasoconstriction responses in I-MetS
mice. This observation is at odds with the potential dele-
terious effect of angiotensin II.
Adiponectin has been addressed as an important vaso-
dilator effector secreted from PVAT, and Greenstein
et al. reported loss of the protective vasodilator effect of
PVAT involving adiponectin in obese patients [16].
Moreover, lower levels of adiponectin, in particular
HMW adiponectin, have been linked to MetS [49]. We
observed decreased HMW adiponectin levels only in
serum of MetS mice.
Another aspect related to PVAT addressed in this
study was activation of the RhoA/Rho-kinase pathway, akey modulator of vascular smooth muscle contraction
[50] and contributor to the pathophysiology of arterial
hypertension [51]. Rho-kinase activity was reported to
be upregulated in leukocytes from patients with MetS
[52] and hypertension [53]. In animal models of hyper-
tension, increased Rho-kinase activity was detected in
vascular tissues [54,55]. More recently Hara et al.
showed that stretching of adipocytes by accumulated
lipid triggers RhoA/Rho-kinase signaling and the subse-
quent expression of inflammatory genes. Therefore,
RhoA/Rho-kinase signaling is implicated in inflamma-
tory changes in adipose tissue in obesity, contributing to
and aggravating weight gain and insulin resistance [56].
Thus, it is plausible to hypothesize that signaling ori-
ginating from PVAT influences vascular contractility.
Interestingly, we saw that although PVAT from I-MetS
mice was already hypertrophied there was no evidence
of Rho-kinase activation; the latter was seen only in
MetS mice, suggesting that the augmented vasocon-
striction in I-MetS occurred independently of PVAT-
derived RhoA/Rho-kinase signaling.
Conclusion
In summary, this study identified distinct patterns of
microvascular dysfunction in MetS, with augmented
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dependent of endothelial dysfunction, insulin resistance,
inflammation, and a dysfunctional PVAT, features com-
monly accepted as modulators of microvascular func-
tion. Our findings strongly suggest that, in I-MetS, the
augmented vasoconstriction was caused by vascular
smooth muscle cell dysfunction. These results shed light
on the link between MetS and increased CVD risk. We
cannot state the relevance of these results to human
MetS. Further research is needed to identify the mecha-
nisms of early microvascular changes and to provide im-
proved preventive strategies aiming to decrease the CVD
risk associated with MetS.
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